INDV

+ Watchlist + Portfolio

Indivior Pharmaceuticals, Inc.

Regulated industry Physical productsTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $35.38
52-Week Range: $22.56 – $42.81
Market Cap: $4.21B
P/E (TTM): 12.80
EPS (TTM): 2.79
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: 26.40%
Gross Margin: 85.72%
Operating Margin: 46.94%
Profit Margin: 26.75%
Current Ratio: 0.83
Debt/Equity: —
Total Debt: $509.00M
Free Cash Flow: $86.50M
Revenue Growth: 13.60%
Earnings Growth: 600.00%
Enterprise Value: $4.50B

INDV Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$901.00M	$1.09B	$1.19B	$1.24B
Cost of Revenue	$151.00M	$174.00M	$231.00M	$246.00M
Gross Profit	$750.00M	$919.00M	$957.00M	$993.00M
Research & Development	$74.00M	$116.00M	$107.00M	$97.00M
Selling, General & Admin	$469.00M	$565.00M	$612.00M	$634.00M
Operating Expenses	$535.00M	$672.00M	$723.00M	$728.00M
Operating Income	$215.00M	$247.00M	$234.00M	$265.00M
EBITDA	-$46.00M	-$95.00M	$89.00M	$304.00M
Pretax Income	-$89.00M	-$145.00M	$20.00M	$239.00M
Income Tax	-$44.00M	-$19.00M	$13.00M	$29.00M
Net Income	-$44.00M	-$126.00M	$7.00M	$210.00M
Diluted EPS	-0.38	0.01	-0.36	1.64
Diluted Shares	145.62M	141.80M	132.31M	128.05M

INDV Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$774.00M	$316.00M	$319.00M	$195.00M
Receivables	—	—	$287.00M	$255.00M
Inventory	$114.00M	$135.00M	$178.00M	$155.00M
Current Assets	$1.26B	$1.27B	$827.00M	$652.00M
Total Assets	$1.77B	$1.76B	$1.32B	$1.20B
Current Liabilities	$1.02B	$1.29B	$924.00M	$914.00M
Long-Term Debt	$237.00M	$237.00M	$315.00M	$290.00M
Total Debt	$277.00M	$283.00M	$375.00M	$351.00M
Total Liabilities	$1.72B	$1.95B	$1.65B	$1.30B
Retained Earnings	$1.30B	-$295.00M	-$443.00M	-$243.00M
Shareholders' Equity	$51.00M	-$192.00M	-$337.00M	-$99.00M
Working Capital	$240.00M	-$24.00M	-$97.00M	-$262.00M
Net Debt	—	—	$14.00M	$124.00M

INDV Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$4.00M	-$300.00M	$36.00M	-$27.00M
Capital Expenditure	-$5.00M	-$53.00M	-$31.00M	-$67.00M
Free Cash Flow	-$9.00M	-$353.00M	$5.00M	-$94.00M
Depreciation & Amortisation	$16.00M	$15.00M	$28.00M	$20.00M
Stock-Based Compensation	$16.00M	$21.00M	$24.00M	$26.00M
Investing Cash Flow	-$222.00M	-$95.00M	$69.00M	-$66.00M
Financing Cash Flow	-$101.00M	-$64.00M	-$102.00M	-$30.00M
Share Repurchases	-$90.00M	-$33.00M	-$173.00M	-$11.00M
Net Change in Cash	-$327.00M	-$459.00M	$3.00M	-$123.00M

INDV Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$266.00M	$302.00M	$314.00M	$358.00M	$317.00M	$343.00M
Cost of Revenue	$44.00M	$52.00M	$83.00M	$67.00M	$40.00M	$50.00M
Gross Profit	$222.00M	$250.00M	$231.00M	$291.00M	$277.00M	$293.00M
Research & Development	$22.00M	$21.00M	$33.00M	$21.00M	$16.00M	$12.00M
Selling, General & Admin	$133.00M	$158.00M	$155.00M	$189.00M	$124.00M	$122.00M
Operating Expenses	$155.00M	$179.00M	$187.00M	$208.00M	$140.00M	$134.00M
Operating Income	$67.00M	$71.00M	$44.00M	$83.00M	$137.00M	$159.00M
EBITDA	$76.00M	$82.00M	$54.00M	$92.00M	$126.00M	$165.00M
Pretax Income	$59.00M	$62.00M	$37.00M	$81.00M	$115.00M	$160.00M
Income Tax	$11.00M	$44.00M	-$5.00M	-$21.00M	$26.00M	$38.00M
Net Income	$47.00M	$18.00M	$42.00M	$102.00M	$89.00M	$122.00M
Diluted EPS	0.38	0.14	0.33	0.79	0.69	0.98
Diluted Shares	123.68M	128.57M	127.27M	129.11M	128.99M	124.00M

INDV Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$372.00M	$510.00M	$445.00M	$195.00M	$175.00M	$222.00M
Receivables	—	—	$272.00M	$255.00M	$285.00M	$287.00M
Inventory	$163.00M	$149.00M	$157.00M	$155.00M	$152.00M	$151.00M
Current Assets	$883.00M	$951.00M	$922.00M	$652.00M	$667.00M	$725.00M
Total Assets	$1.38B	$1.45B	$1.42B	$1.20B	$1.20B	$1.23B
Current Liabilities	$1.00B	$1.06B	$965.00M	$914.00M	$779.00M	$868.00M
Long-Term Debt	$311.00M	$308.00M	$304.00M	$290.00M	$486.00M	$487.00M
Total Debt	$370.00M	$366.00M	$356.00M	$351.00M	$509.00M	$509.00M
Total Liabilities	$1.66B	$1.71B	$1.62B	$1.30B	$1.34B	$1.44B
Retained Earnings	-$406.00M	-$388.00M	-$346.00M	-$243.00M	-$280.00M	-$334.00M
Shareholders' Equity	-$286.00M	-$258.00M	-$207.00M	-$99.00M	-$144.00M	-$207.00M
Working Capital	-$122.00M	-$105.00M	-$43.00M	-$262.00M	-$112.00M	-$143.00M
Net Debt	—	—	—	$124.00M	$311.00M	$265.00M

INDV Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$75.00M	$158.00M	-$39.00M	-$221.00M	-$9.00M	$229.00M
Capital Expenditure	-$5.00M	-$18.00M	-$20.00M	-$24.00M	-$20.00M	-$7.00M
Free Cash Flow	$70.00M	$140.00M	-$59.00M	-$245.00M	-$29.00M	$222.00M
Depreciation & Amortisation	$5.00M	$5.00M	$5.00M	$5.00M	$4.00M	$3.00M
Stock-Based Compensation	$6.00M	$8.00M	$7.00M	$5.00M	$9.00M	$11.00M
Investing Cash Flow	-$5.00M	-$17.00M	-$20.00M	-$24.00M	-$19.00M	-$8.00M
Financing Cash Flow	-$17.00M	-$5.00M	-$3.00M	-$5.00M	$7.00M	-$173.00M
Share Repurchases	-$11.00M	$0.00	$0.00	$0.00	-$126.00M	-$176.00M
Net Change in Cash	$53.00M	$137.00M	-$63.00M	-$250.00M	-$20.00M	$47.00M

Market Snapshot

About

Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to treating substance use disorders and serious mental illnesses. The company's portfolio includes medications for opioid dependence, including buprenorphine-based products marketed under various brand names. Indivior focuses on developing long-acting injectable formulations and abuse-deterrent technologies to improve treatment adherence and patient outcomes. The company combines pharmaceutical development with patient support programs to address the complex challenges of addiction treatment and recovery.